Second lower genital tract squamous cell carcinoma following cervical cancer

2000 ◽  
Vol 79 (9) ◽  
pp. 765-770 ◽  
Author(s):  
ELŻBIETA SENKUS ◽  
TOMASZ KONEFKA ◽  
MONIKA NOWACZYK ◽  
JACEK JASSEM
Keyword(s):  
Cervical Cancer ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Genital Tract ◽  
Lower Genital Tract

scholarly journals Association between polymorphisms in TP53 and XRCC1 genes and the high-risk HPV and tumor markers in women with cervical cancer

2019 ◽  
pp. 26-33
Author(s):  
Ж.Т. Исакова ◽  
В.Н. Кипень ◽  
Н.М. Букуев ◽  
Э.Т. Талайбекова ◽  
К.А. Айтбаев ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Tumor Markers ◽  
Squamous Cell ◽  
Tp53 Gene ◽  
Kyrgyz Republic ◽  
Hpv 16 ◽  
Pcr Rflp ◽  
High Risk Hpv

Цель - оценить ассоциацию генов TР53 (rs1042522) и XRCC1 (rs25487, rs1799782) со статусом по вирусу папилломы человека (ВПЧ) и уровнем онкомаркеров у женщин киргизской национальности с раком шейки матки (РШМ). Материалы и методы. Исследование проведено по типу «случай-контроль» и включало 103 женщин с гистологически верифицированным диагнозом РШМ и 102 женщин без онкологической патологии в анамнезе. Генотипирование пациентов осуществлялось методом ПЦР-ПДРФ. Проведено типировование ВПЧ 16 и 18 типов, в сыворотке крови определены уровни ракового эмбрионального антигена (РЭА) и SCC (squamous cell carcinoma antigen). Результаты. Генотипы Pro/Pro и Arg/Pro полиморфизма p.Arg72Pro гена ТР53 были ассоциированы с наличием у женщин с РШМ ВПЧ 16 типа - ОШ=1,98 (95% ДИ=1,01-3,86, p=0,04), а генотип Pro/Pro полиморфизма p.Arg72Pro гена ТР53 - с ВПЧ 18 типа - ОШ=9,15 (95% ДИ=1,78-46,96, p=0,002). Высокие уровни онкомаркеров РЭА и SCC чаще встречаются у пациентов с РШМ, имеющих размер первичного опухолевого узла более 4 см. Патологически высокие уровни РЭА и SCC ассоциированы преимущественно с ВПЧ 16 типа. Заключение. Наличие аллеля Pro (генотипов Pro/Pro и Pro/Arg) по ОНП p.Arg72Pro (ген ТР53) у женщин с РШМ ассоциировано с положительным статусом по высокоонкогенным ВПЧ 16 и 18 типов. Aim: Evaluation of the role of TР53 (rs1042522), XRCC1 (rs25487, rs1799782) gene depending on the human papillomavirus (HPV), morphological parameters of the tumor and tumor markers of the blood among women with cervical cancer (CC) in Kyrgyz Republic. Methods. This was a case-control study of 205 women of Kyrgyz origin with morphologically verified CC (N=103) and 102 women without cancer and chronic diseases. Genotyping was performed by PCR-RFLP method. HPV 16 and 18 types, levels of squamous cell carcinoma (SCC) and сarcinoembryonic antigen (CEA) tumor markers were detected. Results. A relationship has been identified between the genetic and clinical and biochemical parameters: Pro/Pro и Arg/Pro for single-nucleotide polymorphism p.Arg72Pro of the ТР53 gene were associated with HPV 16 type - OR 1,98 (95% CI=[1,01-3,86]), p=0,04; Pro/Pro for p.Arg72Pro of the ТР53 - with HPV 18 type - OR =9,15 (95% CI=[1,78-46,96]), p=0,002. Among patients with tumor size of more than 4 cm are more common high levels of CEA and SCC tumor markers. High levels of CEA and SCC are associated mainly with type 16 HPV. Conclusions. The results of the present study suggest that the presence of the Pro allele (genotypes Pro/Pro and Pro/Arg) by SNP p.Arg72Pro (TP53 gene) among women with cervical cancer is associated with a positive status for highly oncogenic HPV 16 and 18 types.

A PROSPECTIVE RANDOMIZED STUDY TO COMPARE THE CONCURRENT CHEMO-RADIATION VERSUS HYPO-FRACTIONATED CHEMO-RADIATION IN LOCALLY ADVANCED CERVICAL CANCER.

2021 ◽  
pp. 40-42
Author(s):  
Arpan Jana ◽  
Pabitra Das ◽  
Poulami Gupta ◽  
Phalguni Gupta
Keyword(s):  
Cervical Cancer ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
External Beam Radiotherapy ◽  
Locally Advanced ◽  
Intracavitary Brachytherapy ◽  
External Beam ◽  
Carcinoma Cervix ◽  
Advanced Carcinoma

Background: Concurrent chemo-radiation is the standard treatment worldwide for locally advanced squamous Cell carcinoma cervix. However, conventional chemo-radiotherapy is also associated with unacceptable local and systemic failure rates for locally advanced disease. Biologically squamous cell carcinoma of head- neck cancer and cervical cancer behaves quite similarly in response to radiotherapy. So, it can be expected that, altered fractionation can increase the local control in case of squamous cell carcinoma cervix than conventional radiotherapy. There is no randomised control trial for carcinoma cervix till date, which compares conventional chemo-radiation with hypo-fractionated chemo-radiation. Aims And Objectives: The present study was planned to compare local disease control and acute toxicity of conventional chemo-radiation with hypo-fractionated chemo-radiation in locally advanced carcinoma cervix. Materials And Methods: In Conventional Chemo-radiation Arm A patients (n=30) received external beam radiotherapy 50 Gy in 25 fractions in 5 weeks accompanied by weekly intravenous Cisplatin 40mg/m2 followed by intracavitary brachytherapy 7 Gy per fraction once in a week for 3 weeks. The second group of hypo-fractionated Arm B received external beam radiotherapy 45 Gy in 20 fractions in 4 weeks accompanied by weekly intravenous Cisplatin 40mg/m2 followed by intracavitary brachytherapy 9 Gy per fraction once in a week for 2 weeks. Results: Grade II diarrhea were seen more in Arm B 17 (56.66%) compare to Arm A 12(40%) and grade III diarrhea was seen 4 (3.33%) in Arm B and 2(6.66%) in Arm A. At 2 months and 6 months after completion of treatment Complete response were 25 (83.4%) in Arm A compare to 22 (73.3%) in Arm B and 20 (74.1%) in Arm A and 18 (72%) in Arm B respectively. Conclusion: Hypo-fractioned radiotherapy may be used as an alternate protocol for treatment of locally advanced carcinoma cervix with acceptable toxicities.

Real-world effectiveness of Glasgow prognostic score and tumor biomarkers in predicting post-relapse survival in patients with recurrent cervical cancer after minimally invasive surgery

2020 ◽  
Author(s):  
Junhui Guo ◽  
Yuanyuan Wang ◽  
Xinxin Wang ◽  
Shengli Zhou ◽  
Peimin Liu
Keyword(s):  
Cervical Cancer ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Clinical Data ◽  
Squamous Cell ◽  
Real World ◽  
Prognostic Score ◽  
Glasgow Prognostic Score ◽  
Tumor Biomarkers ◽  
Recurrent Cervical Cancer

Abstract Background Cervical cancer ranks the third most common malignancy of women worldwide, and recurrence of cervical cancer treatment is the major concern. Carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), squamous cell carcinoma antigen (SCCA) and Glasgow Prognostic Score (GPS) were potential prognostic indicator for cervical cancer. However, none of these markers have been evaluated to predict post-relapse survival in recurrent cervical cancer after treatment based on real-world clinical data. Aim To evaluate biomarkers CEA, CA125, SCCA and Glasgow Prognostic Score (GPS) in predicting post-relapse survival in recurrent cervical cancer after treatment based on real-world clinical data. Results Among the 1607 patients, the majority of patients (75.5%) were non-smokers, and the majority of histologic type (68.3%) was squamous cell carcinoma. Except CEA, there were significant difference between different GPS groups in these markers. Areas under the curves (AUC) for GPS, CEA, CA125 and SCCA were 0.632, 0.617, 0.641 and 0.628, respectively. All clinicopathologic characteristics were significantly correlated with CA125. Higher levels of biomarkers and GPS had lower survival and GPS=2 and SCCA was an independent prognostic factor for survival (P=0.008 and P=0.010, respectively). Conclusions In real-world settings, GPS and tumor biomarkers, especially SCCA to independently predict post-recurrence survival in patients with recurrent cervical cancer.

Sign in / Sign up

Export Citation Format

Share Document